Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Patients with Chronic HCV GT1
NCT03143998Phase 4Withdrawn
- Sponsor
- Merck & Co.
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of grazoprevir in hepatitis C (HCV) (4 arms), sponsored by Merck & Co. Primary endpoints: Sustained Virologic Response 12 weeks after end of therapy at 24 weeks, Percentage of participants experiencing an adverse event up to 14 weeks and 1 more. Planned start Feb 2018; status: withdrawn.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03143998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03143998.